Drug trial data look good for dry AMD treatment

Article

Positive interim data results from the Phase II trial of OT-551 to treat geographic atrophy (GA), an advanced form of AMD, have been announced by Othera Pharmaceuticals Inc.

Positive interim data results from the Phase II trial of OT-551 to treat geographic atrophy (GA), an advanced form of AMD, have been announced by Othera Pharmaceuticals Inc.

OT-551 is an eye drop and contains a hydroxylamine anti-oxidative and anti-inflammatory molecule that targets oxidative stress and inflammation pathways, believed to be involved in AMD.

The 12-month findings from the two year OMEGA trial are reported to show an emerging trend for a moderate reduction in vision loss in patients who were treated with OT-551 compared to those receiving a placebo.

“I am particularly excited about these results in light of the absence of any approved treatment today for this slowly progressing, advanced form of dry AMD,” commented Al Reaves, PhD, Othera's Senior Vice President of Clinical Development. “These initial clinical results confirm preclinical findings showing that OT-551 can be administered as an eye drop to affect photoreceptors in the retina. Based on these preliminary results, OT-551 continues to exhibit the excellent safety profile seen in prior studies. Given OT-551’s safety profile and the positive trend on visual acuity, continued follow-up of this elderly population with GA should allow us to profile the drug’s effect on visual acuity and better understand its long term safety.”

Read more about OT-551 in the May issue of Ophthalmology Times Europe magazine. To subscribe click here

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.